Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Med. clín (Ed. impr.) ; 158(5): 206-210, marzo 2022.
Artigo em Espanhol | IBECS | ID: ibc-204359

RESUMO

Objetivo:Pretendemos determinar los factores predictores de enfermedad tromboembólica pulmonar (ETEP) en pacientes con infección por SARS-CoV-2 (COVID-19) atendidos en el servicio de urgencias de un hospital terciario durante la primera ola pandémica.Métodos:Estudio observacional unicéntrico realizado en una cohorte retrospectiva de pacientes con infección confirmada por SARS-CoV-2 (o alta sospecha clínico-radiológica de COVID-19) sometidos a despistaje de ETEP mediante tomografía computarizada de arterias pulmonares (TCAP). Se exploraron los factores predictores de ETEP mediante regresión logística, creándose dos modelos predictivos (sin o con los valores de dímeros-D).Resultados:De un total de 274 TCAP realizados, 70 procedimientos presentaron hallazgos diagnósticos de ETEP, representando una incidencia acumulada del 25,54% (intervalo de confianza [IC] 95%: 20,49-31,14). En el modelo no ajustado por el nivel de dímeros-D, la frecuencia respiratoria >22rpm (odds ratio [OR]: 3,162; IC 95%: 1,627-6,148; p=0,001) y la ausencia de hallazgos sugerentes de COVID-19 en la radiología simple de tórax (OR: 3,869; IC 95%: 0,869-17,225; p=0,076) fueron predictores de ETEP. En el segundo modelo se mantuvo la presencia de taquipnea (OR: 4,967; IC 95%: 2,053-12,018; p<0,001), identificándose además un nivel de dímeros-D>3.000ng/mL (OR: 7,494; IC 95%: 3,038-18,485; p<0,001).Conclusiones:La presencia de taquipnea (>22rpm) y la ausencia de hallazgos radiológicos sugestivos de infección por SARS-CoV-2 en la radiografía simple de tórax, además de los valores de dímero-D>3.000ng/mL, fueron identificados como factores predictores de ETEP en pacientes con COVID-19.


Objective:To determine the predictive factors of pulmonary thromboembolic (PTE) in patients with SARS-CoV-2 infection (COVID-19) assessed in the emergency department at a tertiary hospital during the first pandemic wave.Methods:Observational single-center study conducted in a retrospective cohort of patients with confirmed SARS-CoV-2 infection (or high clinical-radiological suspicion) who underwent PTE screening by computed tomography pulmonary angiography (CTPA). Predictive factors of PTE were explored using logistic regression, creating two predictive models (without or with D-dimer values).Results:Out of a total of 274 CTPA performed, 70 procedures presented diagnostic findings of PTE, representing a cumulative incidence of 25.54% (95% confidence interval [CI]: 20.49-31.14). In the non–D-dimer based model, respiratory rate>22bpm (odds ratio [OR]: 3.162; 95% CI: 1.627-6.148; p=0.001) and the absence of findings suggestive of COVID-19 in plain chest X-ray (OR: 3.869; 95% CI: 0.869-17.225; p=0.076) were predictors of PTE. In the D-dimer-based model, tachypnea remained as a predictive factor (OR: 4.967; 95% CI: 2.053-12.018; p<0.001), as well as D-dimers>3,000ng/ml (OR: 7.494; 95% CI: 3.038-18.485; p<0.001).Conclusions:The presence of tachypnea (>22bpm) and the absence of radiological findings suggestive of SARS-CoV-2 infection in the chest X-ray, in addition to D-dimer values>3,000 ng/mL, were identified as predictive factors of PTE in patients with COVID-19. (AU)


Assuntos
Humanos , Coronavirus , Embolia Pulmonar/diagnóstico por imagem , Embolia Pulmonar/epidemiologia , Estado Terminal , Estudos Retrospectivos , Anticoagulantes
2.
Med Clin (Engl Ed) ; 158(5): 206-210, 2022 Mar 11.
Artigo em Inglês | MEDLINE | ID: mdl-35155814

RESUMO

OBJECTIVE: To determine the predictive factors of pulmonary thromboembolic (PTE) in patients with SARS-CoV-2 infection (COVID-19) assessed in the emergency department at a tertiary hospital during the first pandemic wave. METHODS: Observational single-center study conducted in a retrospective cohort of patients with confirmed SARS-CoV-2 infection (or high clinical-radiological suspicion) who underwent PTE screening by computed tomography pulmonary angiography (CTPA). Predictive factors of PTE were explored using logistic regression, creating two predictive models (without or with D-dimer values). RESULTS: Out of a total of 274 CTPA performed, 70 procedures presented diagnostic findings of PTE, representing a cumulative incidence of 25.54% (95% confidence interval [CI]: 20.49-31.14). In the non-D-dimer based model, respiratory rate >22 bpm (odds ratio [OR]: 3.162; 95% CI: 1.627-6.148; p = 0.001) and the absence of findings suggestive of COVID-19 in plain chest X-ray (OR: 3.869; 95% CI: 0.869-17.225; p = 0.076) were predictors of PTE. In the D-dimer-based model, tachypnea remained as a predictive factor (OR: 4.967; 95% CI: 2.053-12.018; p < 0.001), as well as D-dimers > 3000 ng/mL (OR: 7.494; 95% CI: 3.038-18.485; p < 0.001). CONCLUSIONS: The presence of tachypnea (>22 bpm) and the absence of radiological findings suggestive of SARS-CoV-2 infection in the chest X-ray, in addition to D-dimer values >3000 ng/mL, were identified as predictive factors of PTE in patients with COVID-19.


OBJETIVO: Pretendemos determinar los factores predictores de enfermedad tromboembólica pulmonar (ETEP) en pacientes con infección por SARS-CoV-2 (COVID-19) atendidos en el servicio de urgencias de un hospital terciario durante la primera ola pandémica. MÉTODOS: Estudio observacional unicéntrico realizado en una cohorte retrospectiva de pacientes con infección confirmada por SARS-CoV-2 (o alta sospecha clínico-radiológica de COVID-19) sometidos a despistaje de ETEP mediante tomografía computarizada de arterias pulmonares (TCAP). Se exploraron los factores predictores de ETEP mediante regresión logística, creándose dos modelos predictivos (sin o con los valores de dímeros-D). RESULTADOS: De un total de 274 TCAP realizados, 70 procedimientos presentaron hallazgos diagnósticos de ETEP, representando una incidencia acumulada de 25,54% (intervalo de confianza [IC] 95%: 20,49­31,14). En el modelo no ajustado por el nivel de dímeros-D, la frecuencia respiratoria >22 rpm (odds ratio [OR]: 3,162; IC 95%: 1,627­6,148; p = 0,001) y la ausencia de hallazgos sugerentes de COVID-19 en la radiología simple de tórax (OR: 3,869; IC 95%: 0,869­17,225; p = 0,076) fueron predictores de ETEP. En el segundo modelo se mantuvo la presencia de taquipnea (OR: 4,967; IC 95%: 2,053­12,018; p < 0,001), identificándose además un nivel de dímeros-D > 3.000 ng/mL (OR: 7,494; IC 95%: 3,038­18,485; p < 0,001). CONCLUSIONES: La presencia de taquipnea (>22 rpm) y la ausencia de hallazgos radiológicos sugestivos de infección por SARS-CoV-2 en la radiografía simple de tórax, además de los valores de dímero-D > 3.000 ng/mL, fueron identificados como factores predictores de ETEP en pacientes con COVID-19.

3.
Med Clin (Barc) ; 158(5): 206-210, 2022 03 11.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-34083070

RESUMO

OBJECTIVE: To determine the predictive factors of pulmonary thromboembolic (PTE) in patients with SARS-CoV-2 infection (COVID-19) assessed in the emergency department at a tertiary hospital during the first pandemic wave. METHODS: Observational single-center study conducted in a retrospective cohort of patients with confirmed SARS-CoV-2 infection (or high clinical-radiological suspicion) who underwent PTE screening by computed tomography pulmonary angiography (CTPA). Predictive factors of PTE were explored using logistic regression, creating two predictive models (without or with D-dimer values). RESULTS: Out of a total of 274 CTPA performed, 70 procedures presented diagnostic findings of PTE, representing a cumulative incidence of 25.54% (95% confidence interval [CI]: 20.49-31.14). In the non-D-dimer based model, respiratory rate>22bpm (odds ratio [OR]: 3.162; 95% CI: 1.627-6.148; p=0.001) and the absence of findings suggestive of COVID-19 in plain chest X-ray (OR: 3.869; 95% CI: 0.869-17.225; p=0.076) were predictors of PTE. In the D-dimer-based model, tachypnea remained as a predictive factor (OR: 4.967; 95% CI: 2.053-12.018; p<0.001), as well as D-dimers>3,000ng/ml (OR: 7.494; 95% CI: 3.038-18.485; p<0.001). CONCLUSIONS: The presence of tachypnea (>22bpm) and the absence of radiological findings suggestive of SARS-CoV-2 infection in the chest X-ray, in addition to D-dimer values>3,000 ng/mL, were identified as predictive factors of PTE in patients with COVID-19.


Assuntos
COVID-19 , Embolia Pulmonar , COVID-19/complicações , Produtos de Degradação da Fibrina e do Fibrinogênio , Humanos , Pandemias , Embolia Pulmonar/diagnóstico por imagem , Embolia Pulmonar/epidemiologia , Estudos Retrospectivos , SARS-CoV-2
4.
Endocrinol. nutr. (Ed. impr.) ; 63(4): 145-156, abr. 2016. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-150562

RESUMO

Introducción: El objetivo de esta revisión es evaluar la efectividad para disminuir los eventos adversos clínicos y la seguridad de la insulinoterapia en régimen bolo-basal-corrector o basal-corrector frente a la insulinoterapia en «pauta deslizante», en pacientes con diabetes o con hiperglucemia de reciente diagnóstico ingresados en una planta de hospitalización convencional, no críticos, tanto médica como quirúrgica. Método: Se realizó búsqueda en Medline. La odds ratio fue la medida resumen principal. Se empleó un modelo de efectos aleatorios con la técnica de Mante-Haenszel. Resultados: Novecientas cincuenta y siete citas de las cuales 9 fueron finalmente incluidas en la revisión sistemática. Los pacientes en el grupo BB tuvieron un mejor control glucémico que aquellos con PD. Globalmente, se objetiva una tendencia no significativa hacia un menor riesgo de eventos adversos en el grupo BB frente a PD (OR 0,67 —IC 95%: 0,22-2,04— [I2 = 71%]). Existe una tendencia no significativa hacia un mayor riesgo de hipoglucemia en el grupo BB (OR: 2,29; IC 95% 0,50-10,49 [I2 = 70%]). Conclusión: A pesar de su beneficio para el control glucémico durante la hospitalización, esta revisión no ha objetivado que el uso de la pauta BB disminuya eventos clínicos en pacientes hospitalizados en planta convencional. Debido a la heterogeneidad en los resultados, consideramos que se requieren ensayos clínicos que contemplen su efecto en subgrupos de pacientes en los que la pauta BB se pueda usar de forma segura y con períodos de seguimiento más prolongados (AU)


Introduction: The aim of this review was to assess the effectiveness to reduce clinical adverse events and safety of insulin administered in basal-bolus-corrector or basal-corrector regimens (BB) versus a sliding scale scheme (SS) in patients with diabetes or newly diagnosed hyperglycemia admitted to a conventional (not critical) medical or surgical hospital ward. Method: A Medline search was conducted. The Odds ratio was the main summary measure. A random effects model with the Mantel-Haenszel procedure was used. Results: A total of 957 citations were collected, of which nine were finally included in the systematic review. Patients in the BB group had better blood glucose control than those with SS. Overall, there was a nonsignificant trend to a lower risk of adverse events in the BB as compared to the SS group (OR 0.67 [95% CI 0.22 to 2.04], [I2 = 71%]). There was a nonsignificant trend to an increased risk of hypoglycemia in the BB group (OR 2.29 [95% CI 0.50 to 10.49] [I2 = 70%]). Conclusion: Despite its benefit for glycemic control during hospitalization, this review did not show that use of the BB scheme decreases clinical events in patients hospitalized in a conventional ward. Because of heterogeneity of the results, we think that clinical trials are needed addressing its effect in patient subgroups in which the BB scheme may be used safely and with longer follow-up periods (AU)


Assuntos
Humanos , Insulinas/efeitos adversos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle , Diabetes Mellitus/tratamento farmacológico , Hospitalização/estatística & dados numéricos
5.
Endocrinol Nutr ; 63(4): 145-56, 2016 Apr.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-26826772

RESUMO

INTRODUCTION: The aim of this review was to assess the effectiveness to reduce clinical adverse events and safety of insulin administered in basal-bolus-corrector or basal-corrector regimens (BB) versus a sliding scale scheme (SS) in patients with diabetes or newly diagnosed hyperglycemia admitted to a conventional (not critical) medical or surgical hospital ward. METHOD: A Medline search was conducted. The Odds ratio was the main summary measure. A random effects model with the Mantel-Haenszel procedure was used. RESULTS: A total of 957 citations were collected, of which nine were finally included in the systematic review. Patients in the BB group had better blood glucose control than those with SS. Overall, there was a nonsignificant trend to a lower risk of adverse events in the BB as compared to the SS group (OR 0.67 [95% CI 0.22 to 2.04], [I(2)=71%]). There was a nonsignificant trend to an increased risk of hypoglycemia in the BB group (OR 2.29 [95% CI 0.50 to 10.49] [I(2)=70%]). CONCLUSION: Despite its benefit for glycemic control during hospitalization, this review did not show that use of the BB scheme decreases clinical events in patients hospitalized in a conventional ward. Because of heterogeneity of the results, we think that clinical trials are needed addressing its effect in patient subgroups in which the BB scheme may be used safely and with longer follow-up periods.


Assuntos
Diabetes Mellitus/tratamento farmacológico , Hipoglicemiantes/efeitos adversos , Insulina/efeitos adversos , Hospitalização , Humanos , Hiperglicemia , Hipoglicemiantes/administração & dosagem , Insulina/administração & dosagem
6.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 32(supl.3): 12-17, nov. 2014. tab
Artigo em Espanhol | IBECS | ID: ibc-170832

RESUMO

El interés por la simplificación surge de la necesidad de prescindir de los análogos de nucleósidos, por su toxicidad a largo plazo. Desde hace más de 10 años, en que surgieron los primeros estudios para analizar la seguridad y eficacia de esta estrategia con lopinavir/ritonavir, sigue despertando interés científico, clínico y económico. En el presente no hay un consenso en las recomendaciones; la interpretación de los resultados es discordante, y mientras algunos enfatizan el mayor riesgo de pérdida de la supresión viral, otros destacan que el posible repunte virológico con esta estrategia no se asocia con una pérdida de opciones terapéuticas ni emergencia de resistencias al inhibidor de proteasa potenciado con ritonavir. Este panorama determina las recomendaciones que se pueden hacer en la práctica clínica; casi todos los grupos están de acuerdo en que deben seleccionarse los pacientes candidatos a una simplificación con menos fármacos (AU)


Interest in simplification arises from the need to dispense with nucleoside analogs due to their long-term toxicity. Since the first trials analyzing the safety and effectiveness of the strategy with lopinavir/ritonavir (LPV/r) emerged more than 10 years ago, simplification continues to arouse scientific, clinical and economic interest. At present, there is no consensus on recommendations; interpretations of results are discordant: while some emphasize the greater risk of loss of virologic control, others indicate that the possible virological rebound with this strategy is unrelated to a loss of therapeutic options or to the emergence of resistance to ritonavir-boosted protease inhibitors. This scenario governs the recommendations that can be made in clinical practice; almost all groups agree that candidates should be selected for a simplification strategy with fewer drugs (AU)


Assuntos
Humanos , Ritonavir/uso terapêutico , Lopinavir/uso terapêutico , Inibidores da Protease de HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , Fármacos Anti-HIV/uso terapêutico , Adesão à Medicação , Carga Viral , Equivalência Terapêutica , Inibidores de Integrase de HIV/uso terapêutico , Inibidores da Transcriptase Reversa/uso terapêutico , Aceitação pelo Paciente de Cuidados de Saúde
7.
Thromb Res ; 132(4): 414-9, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23993900

RESUMO

INTRODUCTION: Venous thromboembolism is a common cause of morbidity and mortality. Although cirrhosis has classically been considered as an acquired bleeding diathesis, there is increasing evidence that rejects the traditional belief that these patients are naturally protected against venous thromboembolism. However, antithrombotic prophylaxis in this setting is still underused. The aim of this review is to assess if the use of heparin in cirrhotic patients is effective in the prevention of venous thromboembolism and whether its use is related to an increase in bleeding episodes. MATERIAL AND METHODS: We searched in MEDLINE and EMBASE, using the terms "liver cirrhosis", "heparin", "low molecular weight heparin," "venous thrombosis", "deep venous thrombosis", "hemorrhage" and "bleeding". We sought for clinical trials and observational studies performed in patients with liver cirrhosis to evaluate the efficacy or the safety of the heparin. It was used the Mantel-Haenszel method with a random effects model. Odd Ratio was the main measure of effect. The results of the pooled OR and its 95% confidence intervals were expressed in forest plots. The heterogeneity was assessed by the I(2) statistic. The statistical software RevMan was used. RESULTS AND CONCLUSIONS: The current review found that, although the use of heparin was not related to higher rates of bleeding in cirrhotic patients (pooled OR 0.87 95% CI (0.34-2.18)), it doesn´t decrease the risk of venous thromboembolism in patients receiving prophylaxis, with a pooled OR 1.65 95% (0.36 to 7.54). However, further prospective studies are needed to assess this issue.


Assuntos
Anticoagulantes/uso terapêutico , Heparina/uso terapêutico , Cirrose Hepática/sangue , Trombose Venosa/prevenção & controle , Humanos , Cirrose Hepática/complicações , Trombose Venosa/tratamento farmacológico , Trombose Venosa/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...